A collaborative effort is trying to construct the cell atlas of the developing brains of humans and animal models. Using advanced single-cell and spatial technologies, they mapped how brain cell types emerge, diversify and organize over time, offering new insights into the origins of neurodevelopmental and psychiatric conditions. These breakthroughs in genomics and imaging will allow scientists to study complex developmental processes with high resolution.

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical settings. Many individual studies as well as large projects like the Psychiatric Ratings using Intermediate Markers (PRISM) studies and the Psychiatric Biomarkers Network (PBN) have been looking at multiple biomarker types, and have begun to identify predictors of specific symptoms, or disease progression.

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are working on improving diagnoses by investigating potential biomarkers and collection methods.

Manifold Biotechnologies Inc. has signed a strategic research collaboration and license agreement with F. Hoffmann-La Roche Ltd. to develop next-generation brain shuttles for neurological diseases. The collaboration will apply Manifold’s proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine.